Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiaodong Jia has a total of 211 co-authors. Here are the top co-authors by number of shared publications:

  • Xizi Wang

    Joint Laboratory for Translational Medicine Research, Liaocheng People’s Hospital, Liaocheng, China

    5 shared publications
  • Yinying Lu

    Peking University 302 Clinical Medical School, Peking University, Beijing, China

    5 shared publications
  • Qiang Zhang

    Joint Laboratory for Translational Medicine Research, Liaocheng People’s Hospital, Liaocheng, China

    4 shared publications
  • Lili Yi

    Affiliation Joint Laboratory for Translational Medicine Research, Liaocheng People’s Hospital, Liaocheng, Shandong, China

    3 shared publications
  • Mingliang Gu

    Affiliation Joint Laboratory for Translational Medicine Research, Liaocheng People’s Hospital, Liaocheng, Shandong, China

    3 shared publications
  • Guanglin Lei

    Peking University 302 Clinical Medical School, Peking University, Beijing, Beijing, China

    2 shared publications

Latest Publications

  • Open Access

    Unraveling outcome-related co-expression modules and their impact on the melanoma microenvironment through integration of bulk and single-cell data

    by Xizi Wang, Ying Fu, Zhen Wang, Zhaona Song, Qiang Zhang, Fangjie Guo, Shuzhao Jia, Xianchao Guo, Qiaosong Zheng, Xiaodong Jia

  • Open Access

    Identification and evaluation of gut microbiome as non-invasive biomarkers for early lung adenocarcinoma from a multi-center study

    by Weidong Zhang, Shurui Wu, Leilei Shen, Peng Peng, Rong Li, Qian Zheng, Xiaodong Jia, Qingyan Liu, Yang Liu

    Objective: This study aims to characterize the GM in LUAD patients and develop and validate a GM-based diagnostic model for LUAD. Methods: In this prospective, randomized, multi-center study, the GM was characterized, and an LUAD classifier was developed using a training cohort of 175 early-stage LUAD patients and 107 healthy controls. The model was further validated in a test cohort, two independent external cohorts from Jiangsu and Hainan, and an advanced LUAD cohort. Additional ML models were also developed and compared to assess their predictive performance. Results: LUAD patients exhibited reduced microbial diversity and significantly altered microbial composition compared to healthy controls. The phylum Verrucomicrobia and 13 genera, including Enterococcus and Akkermansia , were more abundant in the LUAD group, while 5 phyla, such as Fusobacteria and Cyanobacteria, and 17 genera, including Lactobacillus and Weissella , were enriched in the control group. Using random forest (RF), eight operational taxonomic units were identified as the optimal subset, achieving an area under the curve (AUC) of 0.998 in the training cohort and maintaining high accuracy in the test cohort (AUC = 96.9%). The model also demonstrated robust performance in two independent cohorts from Jiangsu (AUC = 97.6%) and Hainan (AUC = 82.9%), with strong diagnostic potential for advanced LUAD. Among five common models, the RF model exhibited the highest diagnostic accuracy. Conclusions: This study provides a comprehensive characterization of the gut microbiome in LUAD and develops a diagnostic model based on microbial biomarkers, which is validated across regionally diverse cohorts, highlighting its potential as a reliable and non-invasive screening tool for LUAD.


  • Open Access

    Profiling of the mycobiome and metabolome: a comparative study of benign pulmonary nodules and lung adenocarcinoma

    by Weiyi Zhang, Yuan Dong, Fangyan Chen, Fang Wang, Jiahui Li, Chunxi Liu, Tianyi Liu, Li Han, Xiaodong Jia

    Introduction: Lung adenocarcinoma (LUAD), the most common subtype of non-small cell lung cancer, is a form of malignant pulmonary nodule that requires clinical differentiation from benign pulmonary nodules (BPN). The mechanisms underlying the development of LUAD are complex, and effective non-invasive methods for differentiating BPN from LUAD are lacking. This study aimed not only to distinguish BPN from LUAD using gut fungi and serum metabolites, but also to establish an integrated network of gut fungi–metabolite–cytokine interactions. Methods: Fecal and serum samples from individuals with BPN and patients with LUAD were subjected to internal transcribed spacer sequencing, ultra-performance liquid chromatography–tandem mass spectrometry, and multiplex Luminex assays to quantify gut fungi, metabolites, and cytokines, respectively. Results: A significant difference in gut fungal communities was observed between the BPN and LUAD groups. Multiple genera and species were more abundant in LUAD than in BPN. Docosapentaenoic acid n-6 (DPAn-6), indole-3-propionic acid (IPA), and interferon-γ-induced protein 10 (IP-10) were significantly elevated in the LUAD group. The integrated model established using a combination of gut fungi and metabolites demonstrated excellent performance in distinguishing BPN from LUAD. A network of interactions was established among differentially abundant gut fungi, serum metabolites, and cytokines. Conclusion: Our study identifies a novel panel of fungal and metabolite biomarkers for differentiating between BPN and LUAD, and constructs a multi-omics network that provides new insights into investigating the mechanistic role of gut mycobiota dysbiosis in LUAD.

  • Open Access

    Multi-lineage hepatic organoids reveal toxic exosome mediated indirect hepatotoxicity

    by Lei Sun, Yuying Zhang, Yudi Niu, He Yang, Lyu Zhou, Xiaodong Jia, Yihan Chen, Zhiqiang Liu, Tiantian Wang, Kaini Liang, et al.

    Indirect hepatotoxicity remains a major challenge in drug development because of limited evaluation tools and mechanistic insight. Here, we construct three-dimensional multi-lineage hepatic organoids comprising five liver cell types derived from human embryonic stem cells, and in a screen of 58 hepatotoxic drugs, identify imipramine as an inducer of indirect hepatotoxicity. Imipramine specifically engages tyrosine kinase receptor B expressed by non-parenchymal hepatic stellate cells, activating the p53/hnRNPA2B1/DGCR8 pathway, which drives selective enrichment of microRNA-34a-3p in hepatic stellate cell–derived exosomes, thereby converting them into toxic exosomes. These toxic exosomes transfer microRNA-34a-3p to hepatocytes, where it disrupts cellular homeostasis by downregulating the anti-apoptotic protein XIAP, thereby activating caspase3 and inducing apoptosis. Consistently, imipramine long-term gavage in vivo triggers hepatic stellate cell apoptosis and toxic exosome–mediated hepatocyte injury without direct hepatocyte toxicity. Our findings establish a biomimetic organoid platform for precision drug testing and highlight the central role of intercellular communication in drug-induced liver injury.


  • Open Access

    Whole genome sequencing revealed esophageal squamous cell carcinoma related biomarkers

    by Mingjun Li, Lei Li, Xizi Wang, Yanwei Zhao, Peina Du, Wei Wang, Zhenxing Wang, Yadong Wang, Yanxing Sheng, Mingliang Gu, et al.

    Esophageal squamous cell carcinoma (ESCC) is among the most frequently diagnosed cancer types, and affected patients frequently experience poor prognostic outcomes and high mortality rates. Many genomic studies of ESCC have been performed in recent years, yet the mutational mechanisms driving ESCC and their clinical implications remain incompletely understood. In this study, paired tumor and normal tissue samples from 22 patients with ESCC were used for whole genome sequencing-based analyses of genome-wide mutational events. These comprehensive analyses enabled the detection and characterization of various mutation subtypes in ESCC including somatic single-nucleotide variants, small insertions and deletions, copy number variations, structural variations, and circular extrachromosomal DNA. Of identified genes harboring non-silent mutations, TP53, NOTCH1, CSMD3, EP300, and FAM135B were the most frequently mutated genes in this study and they were annotated in the COSMIC Cancer Gene Census. With the exception of aging-related signatures, an APOBEC-associated mutational signature was the dominant mutational feature detected in ESCC samples, suggesting that APOBEC-mediated cytidine deamination is likely a major driver of mutations in this cancer type. Notably, our study also detected circular extrachromosomal DNA (ecDNA) events in these ESCC patient samples. The oncogenes COX6C, PVT1, and MMP12 as well as the oncogenic long non-coding RNA AZIN1-AS1 which were detected in ecDNA regions in these analyses may be associated with worse disease-free survival in ESCC patients.


  • Open Access

    NLRP6 deficiency enhances macrophage-mediated phagocytosis via E-Syt1 to inhibit hepatocellular carcinoma progression

    by Shuang Li, Yuchen Fu, Xiaodong Jia, Zherui Liu, Zhenwei Qian, Haoran Zha, Guanglin Lei, Lingxiang Yu, Xinfeng Zhang, Ting Zhang, et al.

    Background: Current treatments with tyrosine kinase inhibitors and immune checkpoint inhibitors have limited efficacy for hepatocellular carcinoma (HCC) due to drug resistance. Emerging therapies such as chimeric antigen receptor T (CAR-T) and macrophage-based cell therapies are promising but need to be improved. Objectives: This study investigates the role of macrophage NOD-like receptor family pyrin domain containing 6 (NLRP6) in HCC progression and its therapeutic potential. Design: Immunofluorescence staining was performed in patient samples. Liver tumour models (autonomous, orthotopic, subcutaneous) were developed, and RNA sequencing, flow cytometry and immunohistochemistry were performed in wild-type, Nlrp6 −/− mice, and cell-specific Nlrp6 knockout mice. Phagocytosis was assessed using particles or tumour cells. Multiomics, immunoprecipitation mass spectrometry, western blot and co-immunoprecipitation were performed to examine the interaction between NLRP6’s PYD domain and E-Syt1’s SMP domain. Results: CD68 (a macrophage marker) and NLRP6 expression were detected in patient HCC tissues, and patients with lower macrophage NLRP6 expression had longer survival. Compared with their wild-type mice, Nlrp6 −/− mice and macrophage cell-specific Nlrp6 knockout mice showed delayed tumour growth. Adoptive transfer of Nlrp6 −/− macrophages reduced tumour growth in vivo. Macrophages from Nlrp6 −/− mice were more abundant and exhibited enhanced phagocytosis compared with those from wild-type mice. Co-immunoprecipitation and phagocytosis experiments revealed E-Syt1 promoted phagocytosis, which was negatively regulated by NLRP6 through interaction with its PYD domain. Conclusions: NLRP6 promotes HCC progression by inhibiting macrophage infiltration and suppressing phagocytosis via the interaction between its PYD domain and E-Syt1’s SMP domain. Transfer of Nlrp6 −/− macrophages is a promising therapeutic strategy for reducing HCC tumour growth.


  • Open Access

    scRNA-seq and scATAC-seq analyses highlight the role of TNF signaling pathway in chronic obstructive pulmonary disease model mice

    by Qiang Zhang, Li Zhou, Lindong Yuan, Ruihua Zhang, Shanshan Pan, Xizi Wang, Lili Yi, Fengjiao Yuan, Xianchao Guo, Mingliang Gu, et al.

    Chronic obstructive pulmonary disease (COPD) is a prevalent and progressive form of respiratory disease in which patients exhibit persistent respiratory damage affecting the alveoli and/or airway due to exposure to toxic gases or particulate matter. C57BL/6 mice were exposed to cigarette smoke and lipopolysaccharide to establish a COPD model mice, followed by scATAC (Assay for Transposase Accessible Chromatin) sequencing and scRNA sequencing of lung tissue samples. The resultant data revealed consistent findings between scATAC-seq and scRNA-seq regarding cell types, differentially expressed genes, and signaling pathways in COPD model mice. Tumor necrosis factor (TNF) signaling pathway enrichment was evident in the scRNA-seq and scATAC-seq datasets, with similar trends in monocytes/macrophages, dendritic cells, and B cells. In COPD model mice, significant tumor necrosis factor receptor 1 (TNFR1) upregulation and high levels of activity related to cellular communication were observed, and significant increases in Il1b, Csf1, and Bcl3 site accessibility were evident in cells. These findings suggest that the TNF signaling pathway maybe associated with COPD.


  • Open Access

    Profiling the cell diversity and tissue structure of aqueous humor circulatory system in human eyes using spatial single-cell RNA sequencing

    by Hao Yuan, Zhaona Song, Xiao Sun, Chunping Song, Lidong Guo, Qiang Zhang, Yonglun Luo, Chengfu Yuan, Jianlu Gao, Xiaodong Jia


  • Open Access

    Identification of regulatory genes associated with POAG by integrating expression and sequencing data

    by Xizi Wang, Qiang Zhang, Dongdong Zhao, Xiaofen Li, Lili Yi, Siyuan Li, Xin Wang, Mingliang Gu, Jianlu Gao, Xiaodong Jia

    Background: Primary open-angle glaucoma (POAG) is a subtype of glaucoma that accounts for 60%similar to 70% of all cases. Its pathogenic mechanism is intricate and its pathogenic process is concealed. Numerous significant biological processes associated with POAG continue to be elucidated. Methods: In this study, by exploring the expression data of POAG tissues and normal tissues, we mined the regulatory lncRNAs and mRNAs closely associated with the pathogenesis and progression of POAG by exploring a regulatory network of competing endogenous RNA (ceRNA), established by integrating gene expression data with the known lncRNA-miRNA and miRNA-mRNA-regulatory interactions. The key regulatory pathways and regulatory elements of POAG were identified by topological analysis. Simultaneously, the exome data of 28 cases with POAG and healthy controls were analyzed to identify high-frequency mutations and genes. Results: A total of 2712 differentially expressed genes were identified, including 1828 mRNAs and 884 lncRNAs. Network analysis suggested that lncRNAs such as HAGLR, HOTAIR and MIR29B2CHG, and mRNAs such as PPP6R3, BMPR2 and CFL2, may be involved in the onset and progression of POAG. In addition, 55 mutations with potential pathogenicity were identified. Conclusion: These genes and mutations provide novel potential genetic heterogeneity and genetic susceptibility of POAG, as well as fresh suggestions for elucidating the molecular mechanism underlying the pathogenesis of POAG.

  • Open Access

    Identification of copper metabolism-related markers in Parkinson’s disease

    by Jie Lin, Guifeng Zhang, Bo Lou, Yi Sun, Xiaodong Jia, Meidan Wang, Jing Zhou, Zhangyong Xia

    This study aimed to identify key genes related to copper metabolism in Parkinson's disease (PD), providing insight into their roles in disease progression. Using bioinformatic analyses, the study identified hub genes related to copper metabolism in PD patients. Differentially expressed genes (DEGs) were identified using the limma package, and copper-metabolism-related genes (CMRGs) were sourced from the Genecard database. Immune cell-related genes were derived through immune infiltration and Weighted Gene Co-expression Network Analysis (WGCNA). Hub genes were pinpointed by integrating DEGs, CMRGs, and immune cell-related genes. Functional analyses included Receiver Operating Characteristic (ROC) analysis, Ingenuity Pathway Analysis (IPA), and networks for miRNA-mRNA-transcription factor (TF), Competitive Endogenous RNA (ceRNA), and hub gene-drug interactions. Validation was performed in cerebrospinal fluid (CSF) samples from PD patients, while in vitro experiments utilized GBE1- overexpressing SH-SY5Y cells to examine cell proliferation, migration, and viability. Nine hub genes (HPRT1, GLS, SNCA, MDH1, GBE1, DDC, STXBP1, ACHE, and AGTR1) were identified from 753 CMRGs, 416 DEGs, and 951 immune cell-related genes. ROC analysis showed high predictive accuracy for PD, and principal component analysis (PCA) effectively distinguished PD patients from controls. IPA identified 20 significant pathways, and various networks highlighted miRNA, TF, and drug interactions with the hub genes. Hub gene expression was validated in PD CSF samples. GBE1-overexpressing cells displayed enhanced proliferation, migration, and viability. The study identified nine copper metabolism-related genes as potential therapeutic targets in PD, highlighting their relevance in PD pathology and possible treatment pathways.